Replication Competent Lentivirus (RCL)
Showing 1 - 25 of 875
Solid and Hematological Malignancies Trial in United States (Axicabtagene Ciloleucel, Brexucabtagene Autoleucel, KITE-585)
Enrolling by invitation
- Solid and Hematological Malignancies
- Axicabtagene Ciloleucel
- Brexucabtagene Autoleucel (KTE-X19)
-
Duarte, California
- +7 more
Jun 29, 2022
Lentiviral Gene Therapy (Zamtocabtagene Autoleucel) LTFU
Not yet recruiting
- Non Hodgkin Lymphoma
- Long-term Follow-Up
-
Stanford, California
- +4 more
Oct 30, 2023
Patients Previously Treated WithMustang Bio CAR-T Cell
Enrolling by invitation
- Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
- +10 more
- Prior MB-102 CAR-T cell investigational product.
- Prior MB-106 CAR-T cell investigational product.
-
Duarte, California
- +4 more
Dec 8, 2022
Follicular Lymphoma (FL) Trial (biological, drug, other)
Not yet recruiting
- Follicular Lymphoma (FL)
- Tisagenlecleucel
- +4 more
- (no location specified)
May 24, 2023
Cervical Cancer, Head and Neck Squamous Cell Carcinoma, Carcinoma of Vagina Trial in Shanghai (HRYZ-T101 Injection, Fludarabine
Not yet recruiting
- Cervical Cancer
- +5 more
- HRYZ-T101 Injection
- Fludarabine + Cyclophosphamide
-
Shanghai, Shanghai, ChinaFudan University Shanghai Cancer Center
Jul 17, 2023
ß-thalassemia Trial in Shenzhen (ß-globin restored autologous hematopoietic stem cells)
Recruiting
- β-thalassemia
- β-globin restored autologous hematopoietic stem cells
-
Shenzhen, Guangdong, ChinaShenzhen Children's Hospital
Feb 24, 2023
Sickle Cell Disease Trial in Paris (DREPAGLOBE drug product)
Active, not recruiting
- Sickle Cell Disease
- DREPAGLOBE drug product
-
Paris, FranceDepartment of Biotherapy, Necker-Enfants Malades Hospital
Sep 26, 2022
MPS-IH (Hurler Syndrome) Trial in Worldwide (Experimental: OTL-203, Active Comparator: Allo-HSCT)
Not yet recruiting
- MPS-IH (Hurler Syndrome)
- Experimental: OTL-203
- Active Comparator: Allo-HSCT
-
Oakland, California
- +6 more
Nov 27, 2023
Leukemia, Acute Lymphoblastic, Lymphoma, Non-Hodgkin Trial in Ribeirao Preto (CART-19)
Not yet recruiting
- Leukemia, Acute Lymphoblastic
- Lymphoma, Non-Hodgkin
- CART-19
-
Ribeirao Preto, Sao Paulo, BrazilRibeirao Preto School of Medicine, University of Sao Paulo
Oct 23, 2023
Tumors Trial in Worldwide (Letetresgene autoleucel)
Active, not recruiting
- Neoplasms
- Letetresgene autoleucel
-
Pittsburgh, Pennsylvania
- +5 more
Aug 7, 2023
Synovial Sarcoma, Malignant Peripheral Nerve Sheath Tumor (MPNST), Neuroblastoma Trial in United States (Afamitresgene
Not yet recruiting
- Synovial Sarcoma
- +3 more
- Afamitresgene autoleucel
-
Palo Alto, California
- +3 more
Dec 6, 2022
Diffuse Large B-cell Lymphoma (DLBCL) Trial in Worldwide (CTL019)
Completed
- Diffuse Large B-cell Lymphoma (DLBCL)
- Tisagenlecleucel
- Lymphodepleting chemotherapy
-
San Francisco, California
- +25 more
Jan 27, 2023
B Cell Non-Hodgkin's Lymphoma Trial in Duarte (CD19/CD20-directed CAR-T cells)
Recruiting
- B Cell Non-Hodgkin's Lymphoma
- CD19/CD20-directed CAR-T cells
-
Duarte, CaliforniaCity of Hope Medical Center
Aug 10, 2022
Cerebral Adrenoleukodystrophy Who Were Treated With Lenti-D Drug
Enrolling by invitation
- Cerebral Adrenoleukodystrophy (CALD)
- +2 more
- Lenti-D
-
Los Angeles, California
- +10 more
Nov 4, 2022
Fabry Disease Who Received Lentiviral Gene Therapy in Study
Enrolling by invitation
- Fabry Disease
- Safety and Efficacy Assessments
-
Melbourne, Parkville VIC, Australia
- +2 more
Oct 5, 2022
B-cell Non Hodgkin Lymphoma Trial in Seoul (AT101(Anti-CD19 Chimeric Antigen Receptor T cell))
Recruiting
- B-cell Non Hodgkin Lymphoma
- AT101(Anti-CD19 Chimeric Antigen Receptor T cell)
-
Seoul, Korea, Republic ofAsan Medical Center
May 24, 2022
Transfusion Dependent Beta-Thalassemia Trial in Nanning (GMCN-508B (LentiRed))
Recruiting
- Transfusion Dependent Beta-Thalassemia
- GMCN-508B (LentiRed)
-
Nanning, Guangxi, ChinaThe affiliated hospital of guangxi medical university
Feb 28, 2023
Metastatic HER2 Positive Gastroesophageal Junction Cancer Trial in La Jolla, Washington, Hackensack (CYNK-101, Pembrolizumab,
Recruiting
- Metastatic HER2 Positive Gastroesophageal Junction Cancer
- CYNK-101
- +6 more
-
La Jolla, California
- +2 more
Jul 12, 2022
Solid Tumor Trial in Nanjing (RD133)
Recruiting
- Solid Tumor
-
Nanjing, Jiangsu, ChinaThe First Affiliated Hospital with Nanjing Medical University
Dec 8, 2021
Advanced Solid Tumor Trial in Dallas (TCRT-ESO-A2)
Withdrawn
- Advanced Solid Tumor
- TCRT-ESO-A2
- (no location specified)
Aug 31, 2022
Non-Hodgkin Lymphoma Trial in Worldwide (Tisagenlecleucel after optional bridging and lymphodepleting chemo, Platinum-based
Active, not recruiting
- Non-Hodgkin Lymphoma
- Tisagenlecleucel after optional bridging and lymphodepleting chemotherapy
- Platinum-based immunochemotherapy followed in responding patients with high dose chemotherapy and autologous hematopoietic stem cell transplant (HSCT)
-
La Jolla, California
- +66 more
Jan 6, 2023
Relapsed/Refractory Multiple Myeloma, Plasma Cell Leukemia Trial (CAR-T (CAR-GPRC5D))
Not yet recruiting
- Relapsed/Refractory Multiple Myeloma
- Plasma Cell Leukemia
- CAR-T (CAR-GPRC5D)
- (no location specified)
Feb 26, 2023
Artemis (DCLRE1C ) Deficient Severe Combined Immunodeficiency Trial in Paris (ARTEGENE drug product)
Not yet recruiting
- Artemis (DCLRE1C ) Deficient Severe Combined Immunodeficiency
- ARTEGENE drug product
-
Paris, FranceDepartment of Pediatric Immunology, Hematology and Rheumatology
Sep 26, 2022
B-cell Non-Hodgkin's Lymphoma Trial (Fully Human Anti-CD19/CD22 Dual Target Chimeric Antigen Receptor Autologous T Cell
Not yet recruiting
- B-cell Non-Hodgkin's Lymphoma
- Fully Human Anti-CD19/CD22 Dual Target Chimeric Antigen Receptor Autologous T Cell Injection
- (no location specified)
Oct 12, 2021